From these answers, the JF response to the question about generic Relenza sounds cryptic at best and misleading at worst.If GSK will go generic with Relenza after the patent expires, its game over for Biota, so his answer was plain wrong.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
